| Literature DB >> 14735196 |
L R Hiorns1, T D Bradshaw, L A Skelton, Q Yu, L R Kelland, B Leyland-Jones.
Abstract
Specific chromosomal abnormalities are increasingly recognised to be associated with particular tumour subtypes. These cytogenetic abnormalities define the sites of specific genes, the alteration of which is implicated in the neoplastic process. We used comparative genomic hybridisation (CGH) to examine DNA from different breast and ovarian cancer cell lines for variations in DNA sequence copy number compared with the same normal control. We also compared different sources of the MCF7 breast line by both CGH and cDNA expression arrays. Some of the differences between the subcultures were extensive and involved large regions of the chromosome. Differences between the four subcultures were observed for gains of 2q, 5p, 5q, 6q, 7p, 7q, 9q, 10p, 11q, 13q, 14q, 16q, 18p and 20p, and losses of 4q, 5p, 5q, 6q, 7q, 8p, 11p, 11q, 12q, 13q, 15q, 19p, 19q, 20p, 21q, 22q and Xp. However, few variations were found between two subcultures examined, 5 months apart, from the same initial source. The RNA arrays also demonstrated considerable variation between the three different subcultures, with only 43% of genes expressed at the same levels in all three. Moreover, the patterns of the expressed genes did not always reflect our observed CGH aberrations. These results demonstrate extensive genomic instability and variation in RNA expression during subculture and provide supportive data for evidence that cell lines do evolve in culture, thereby weakening the direct relevance of such cultures as models of human cancer. This work also reinforces the concern that comparisons of published analyses of cultures of the same name may be dangerous.Entities:
Mesh:
Substances:
Year: 2004 PMID: 14735196 PMCID: PMC2409579 DOI: 10.1038/sj.bjc.6601405
Source DB: PubMed Journal: Br J Cancer ISSN: 0007-0920 Impact factor: 7.640
Figure 1Idiogram of the human karyotype showing regions of amplification (green) and deletion (red) in DNA from the MCF7 cell line from different sources: (a) University of Nottingham; (b) Institute of Cancer Research (Sutton); (c) McGill University (Montreal) April 1996; and (d) McGill University (Montreal) August 1996.
Amplifications (green) and deletions (red) of genomic sequences identified in ovarian tumours and the ovarian tumour-derived cell lines: Ovcar, A2780, 41M and CH1
Figure 2Clonetech ‘Cancer Array’ filters hybridised with cDNA from MCF7 sublines from different sources: (a) University of Nottingham; (b) Institute of Cancer Research (Sutton); and (d) McGill University (Montreal). Each hybridisation was to a new replicate filter; (none were reprobed).
Comparative expression levels of the 45% of genes differentially expressed between at least two of the cell lines
| 1p13.21 | rhoC | 3.87 | 6.48 | 3.69 |
| 1p13.3 | Glutathione- | 7.40 | 3.57 | 3.47 |
| 2p10–12 | rhoB | 15.29 | 10.63 | 3.61 |
| 2q33–34 | IGFBP2 | — | 6.43 | — |
| 3p21.3 | rhoA H12 | 14.92 | 7.02 | 7.23 |
| 3p21.3 | Laminin receptor | 18.21 | 15.00 | 9.11 |
| 3p21.3 | Semaphorin | — | 3.54 | — |
| 4q12 | PDGF-associated protein | 7.49 | — | — |
| 5q12 | CyclinB1 (CCNB1) | 3.61 | — | — |
| 5q31.3 | Early growth response protein (EGR1) | 8.21 | 7.48 | — |
| 5q31 | Interleukin-13 precursor | 3.70 | 3.49 | — |
| 5q31 | Alpha 1 catenin | 3.69 | — | — |
| 6p21.2 | CDKN1,WAF1 | 6.62 | 6.45 | 9.06 |
| 8p12 | T-plasminogen activator | 5.98 | 4.11 | — |
| 9p12 | Bcl-2 binding athanogene-1 (BAG-1) | 3.95 | — | — |
| 9q22 | Ninjurin-1 | 8.20 | 5.58 | 5.45 |
| 9q34.3 | NOTCH1 | 3.82 | — | 11.22 |
| 10q24 | Cytohesin-1 | 4.26 | 4.02 | 2.63 |
| 11p13 | CD59 | 5.24 | — | — |
| 11p15.4–15.5 | rhoG | 3.57 | — | 3.42 |
| 11q13 | Fau | 12.61 | — | 16.58 |
| 12p13 | CD9 | 11.94 | 5.48 | — |
| 12p13 | CD27BP /SIVA | 13.97 | 4.93 | 8.81 |
| 12q13 | Cytokeratin 8 | 17.17 | 15.00 | 9.10 |
| 12q13 | Cytokeratin 18 | 18.21 | 15.00 | 9.10 |
| 12q14 | CDK4 | 6.32 | 3.00 | 3.75 |
| 14q24.3 | c-fos | 3.35 | 3.46 | — |
| 16p11.2 | MAP kinase 1 | 3.95 | — | 2.28 |
| 16p13.3 | Netrin-2 | — | 6.97 | — |
| 16p13.3 | Nm23-H4 | 3.70 | 5.53 | 8.03 |
| 17q21–22 | Cytokeratin 10 | 11.06 | 3.42 | 4.46 |
| 17q21–22 | Cytokeratin 19 | 18.17 | 13.85 | 9.11 |
| 17q21 | Desmoplakin III | 6.57 | 6.39 | 13.33 |
| 17q21.3 | NDP kinase A (NM23-H1) | 4.69 | 4.93 | 3.05 |
| 17q21.3 | NDP kinase B (NM23-H2) | 18.21 | 15.00 | 11.59 |
| 17q21.32 | Integrin beta 3 | — | 3.79 | — |
| 17q24–25 | EGFRBP-GRB2 | 3.49 | — | — |
| 17q25.3 | Rho GDP dissociation inhibitor 1 | 8.53 | 5.99 | 10.10 |
| 19p13.2 | UV excision repair protein RAD23A | 5.65 | — | 14.71 |
| 19p13.3 | CDC34 | — | 3.06 | 4.78 |
| 19q13 | Apoptosis regulator bax | 4.29 | 4.15 | 5.14 |
| 19 | Macrophage migration inhibitory factor (MIF) | 12.31 | 3.93 | 11.62 |
| 20p13 | CDC25B | 4.29 | — | 2.56 |
| 21q22.1 | Cytosolic superoxide dismutase (SOD1) | 13.73 | 3.21 | 7.53 |
| 22q11 | DVL1 | 3.90 | — | — |
| Xp11.23 | PCTK1 | — | — | 2.84 |
| Xp11.23–3 | EPA/TIMP-1 | — | 6.95 | 4.26 |
| Xq25 | Hepatoma-derived growth factor (HDGF) | 10.00 | 6.93 | 19.53 |
| CD147 antigen | 7.13 | 14.41 | 13.39 | |
| Zyxin-related protein ZRP-1 | 10.12 | — | 8.08 | |
| Cytokeratin 7 | 5.30 | 5.60 | 5.38 | |
| Cytokeratin 16 | 5.24 | 4.47 | — | |
| rhoHP1 | 5.84 | 7.10 | — | |
| P21-rac1, ras-like protein TC25 | 5.85 | — | — | |
| PLK1 | 4.80 | — | — | |
| PDCD2 | 4.14 | — | — | |
| CASP2 | 3.22 | — | — | |
| FAST kinase | 3.94 | — | 3.66 | |
| CDK5 | 4.02 | — | 2.50 | |
| c-myc-binding protein MM-1 | 13.06 | 6.85 | 4.56 | |
| Cytokeratin 5 | — | — | 2.80 | |
| PIG12 | — | — | 4.12 | |
| Integrin-beta 8 precursor | — | — | 2.30 | |
| IGFBP5 | — | — | 3.49 |
Ratio of signal intensity to background. MCF7 sources: (a) University of Nottingham, (b) Institute of Cancer Research (Sutton), and (d) McGill University (Montreal).
Figure 3CGH ratio profiles and accompanying idiograms for selected chromosomes for the three MCF7 cell lines: (a) University of Nottingham; (b) Institute of Cancer Research (Sutton); and (d) McGill University (Montreal). The ratio profiles are shown together with the threshold lines for amplification in green on the right and deletion in red on the left. The areas which exceed the threshold are also illustrated in green or red alongside the idiogram. The heterochromatic regions (which are excluded from the analysis) are shown hatched on the idiogram.